INSILICO Stock Surges Over 10% After Establishing First Industry Longevity Committee

Stock News04-22 11:10

INSILICO (03696) saw its gains expand to over 10%. At the time of writing, the stock was up 9.73%, trading at HK$75, with a turnover of HK$318 million. The company announced the formation of the industry's first Longevity Committee, aimed at providing scientific oversight and strategic guidance for AI-driven aging research and drug discovery. The initiative is designed to empower the development of therapeutics targeting the underlying biological mechanisms of aging, facilitating a shift from reactive disease care to proactive healthspan and peak lifespan extension. The committee's focus areas include research on lifespan models, development of aging biomarkers, identification of dual-purpose targets relevant to both aging and disease, and clinical validation of treatments impacting key hallmarks of aging through biomarkers and foundational models. Dr. Andrew Adams, Vice President of Molecular Discovery Group at Eli Lilly, will serve as the committee chair, a key role expected to bridge cutting-edge longevity science with large-scale pharmaceutical R&D.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment